2019 American Transplant Congress
Outcomes of Liver Transplantation for Mixed Hepatocellular-Cholangiocarcioma
1Columbia University Medical Center, New York, NY, 2Weill Cornell Medicine, New York, NY
*Purpose: Mixed hepatocholangiocarcinomas (HCC-CCA) are rare tumors with both hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) differentiations. They are usually associated with a worse prognosis than…2019 American Transplant Congress
Resource Utilization in Hepatocellular Carcinoma Liver Transplantation before and after the Six Month Wait Time
1Tampa General Hospital, Tampa, FL, 2University of South Florida, Tampa, FL
*Purpose: The purpose of this study was to determine any difference in resource utilization since the implementation of the mandatory six month wait-time policy for…2018 American Transplant Congress
Impact of Mammalian Target of Rapamycin Inhibitors on Hepatocellular Carcinoma Recurrence after Liver Transplant
Despite limited benefit to patients within Milan criteria on explant, mTORi are routinely utilized for prevention of hepatocellular carcinoma (HCC) recurrence after liver transplantation (LT).…2018 American Transplant Congress
Liver Transplantation for Patients with Hepatocellular Carcinoma Presenting beyond Milan Criteria: Analysis of 789 Patients from the US Multicenter HCC Transplant Consortium
Objective: OPTN has recently approved MELD prioritization for HCC patients beyond Milan Criteria (MC) who are downstaged (DS) with locoregional therapy (LRT) prior to liver…2018 American Transplant Congress
Liver Transplantation for Hepatocellular Carcinoma Outperform Other Populations in the New Hepatitis C Era
Background: Long term results of HCC liver transplants (LTx) in the recent era of direct-acting antivirals (DAA) against hepatitis C (HCV) are not available. We…2018 American Transplant Congress
Improving Prognostication amongst Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma: An International, 16-Center Study to Validate and Recalibrate HALTHCC
Objective: Prognosticating outcomes in liver transplant (LT) for hepatocellular carcinoma (HCC) continues to challenge the field. Whereas adoption of the binary Milan Criteria (MC) generalized…2018 American Transplant Congress
Predictive Value of mRECIST in HCC Response to the Neoadjuvant Locoregional Therapies and Prognosis Affected by the Peak AFP Level before Liver Transplantation
PURPOSE: The modified response evaluation criteria in solid tumors (mRECIST) has been used to assess the response of hepatocellular carcinoma (HCC) to locoregional therapy (LRT)…2018 American Transplant Congress
HLA-DR4 Matching and Hepatocellular Carcinoma Recurrence after Liver Transplantation
PURPOSE: The phenomenon of graft versus host disease after orthotopic liver transplantation (OLT) is estimated at approximately 1-2%, suggesting that under some circumstances, the graft…2018 American Transplant Congress
Vascular Invasion and Survival after Liver Transplantation for Hepatocellular Carcinoma: A Study from the European Liver Transplant Registry
PurposeStudies suggest that vascular invasion may be a superior prognostic marker compared with traditional selection criteria, e.g. Milan criteria. We aimed to investigate the prognostic…2018 American Transplant Congress
Post-Transplant Outcomes under the New HCC Exception Policy
Surgery, Johns Hopkins Medical Institute, Baltimore, MD.
In October 2015, OPTN implemented a new policy for liver allocation, under which hepatocellular carcinoma (HCC) patients receive exception points only after a 6-month delay.…
- « Previous Page
- 1
- …
- 10
- 11
- 12
- 13
- 14
- …
- 23
- Next Page »